A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Exclusion Criteria

• •History of malabsorption syndrome or other condition that would interfere with enteral absorption
• •Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytic agents
• •Prior anti-cancer therapy (e.g., chemotherapy, biologic therapy, radiotherapy, or hormonal therapy) within 4 weeks or 5 half-lives (whichever is shorter) of the first dose of study treatment
• •Uncontrolled current illness
• •Active small or large intestine inflammation (such as Crohn's disease or ulcerative colitis)
• •Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
• •Known HIV infection
• •New York Heart Association (NYHA) Class II or greater congestive heart failure
• •Active ventricular arrhythmia requiring medication
• •Pregnancy, lactation, or breastfeeding
• •Known significant hypersensitivity to study drugs or excipients
• •History of arterial thromboembolic disease within 6 months of first study treatment
• •No more than two prior chemotherapy regimens for metastatic disease